000963 华东医药
已收盘 10-22 15:00:00
资讯
新帖
简况
瑞银将华东医药评级下调至中性，目标价28元。
格隆汇 · 10-22 19:06
瑞银将华东医药评级下调至中性，目标价28元。
佐力药业：公司及子公司与华东医药的购销属于商业化业务往来
证券之星 · 10-22 17:12
佐力药业：公司及子公司与华东医药的购销属于商业化业务往来
瑞银：降联邦制药评级至“中性” 重申先声药业为首选
同花顺 · 10-22 16:47
瑞银：降联邦制药评级至“中性” 重申先声药业为首选
华东医药（000963）披露控股子公司获得药物临床试验批准通知书，10月19日股价上涨0.91%
证券之星 · 10-19
华东医药（000963）披露控股子公司获得药物临床试验批准通知书，10月19日股价上涨0.91%
全球首创三靶点激动剂DR10624入选AASLD最新突破摘要 华东医药代谢领域布局再获国际认可
同花顺 · 10-19
全球首创三靶点激动剂DR10624入选AASLD最新突破摘要 华东医药代谢领域布局再获国际认可
华东医药最新公告：控股子公司注射用DR30206获批开展Ⅲ期非小细胞肺癌临床试验
证券之星 · 10-16
华东医药最新公告：控股子公司注射用DR30206获批开展Ⅲ期非小细胞肺癌临床试验
华东医药（000963）10月15日主力资金净卖出3845.29万元
证券之星 · 10-16
华东医药（000963）10月15日主力资金净卖出3845.29万元
华东医药（000963）9月30日主力资金净买入8495.75万元
证券之星 · 10-08
华东医药（000963）9月30日主力资金净买入8495.75万元
华东医药（000963）披露2026年半年度报告，9月30日股价上涨3.13%
证券之星 · 09-30
华东医药（000963）披露2026年半年度报告，9月30日股价上涨3.13%
华东医药：创新药收入占医药工业营收比重达到50%为公司争取达成的阶段性努力方向
证券之星 · 09-30
华东医药：创新药收入占医药工业营收比重达到50%为公司争取达成的阶段性努力方向
华东医药：HDM1002片是公司内分泌/代谢赛道重点自研创新品种
证券之星 · 09-29
华东医药：HDM1002片是公司内分泌/代谢赛道重点自研创新品种
华东医药：创新产品业务收入占比将稳步提升
证券之星 · 09-29
华东医药：创新产品业务收入占比将稳步提升
华东医药：HDM1002、HDM1005、DR10624为该治疗领域的重点在研产品
证券之星 · 09-29
华东医药：HDM1002、HDM1005、DR10624为该治疗领域的重点在研产品
华东医药：HDM1002拥有亮眼的减重Ⅲ期临床结果与差异化优势
证券之星 · 09-29
华东医药：HDM1002拥有亮眼的减重Ⅲ期临床结果与差异化优势
华东医药HDM1002片取得顶线结果 未来商业化价值几何？
新浪证券 · 09-29
华东医药HDM1002片取得顶线结果 未来商业化价值几何？
华东医药：HDM1005体重管理适应症中国III期临床研究已于近期顺利达成40周主要终点的期中分析
证券之星 · 09-28
华东医药：HDM1005体重管理适应症中国III期临床研究已于近期顺利达成40周主要终点的期中分析
华东医药最新公告：全资子公司创新GLP-1靶点口服小分子激动剂HDM1002片减重Ⅲ期研究获得积极顶线结果
证券之星 · 09-27
华东医药最新公告：全资子公司创新GLP-1靶点口服小分子激动剂HDM1002片减重Ⅲ期研究获得积极顶线结果
华东医药：工业微生物板块持续夯实xRNA原料、特色原料药&中间体、大健康&生物材料、动物保健四大业务布局
证券之星 · 09-24
华东医药：工业微生物板块持续夯实xRNA原料、特色原料药&中间体、大健康&生物材料、动物保健四大业务布局
华东医药加快再生医美布局，欣可丽美学独家合作引入ECM胶原蛋白MB007
中金财经 · 09-17
华东医药加快再生医美布局，欣可丽美学独家合作引入ECM胶原蛋白MB007
华东医药：目前和解谈判仍在推进过程中
证券之星 · 09-17
华东医药：目前和解谈判仍在推进过程中
加载更多
公司概况
公司名称：
华东医药股份有限公司
所属行业：
零售业
上市日期：
2000-01-27
主营业务：
华东医药股份有限公司的主营业务是专科、慢病及特殊用药领域的研发、生产和销售。公司的主要产品是慢性肾病用药、免疫用药、肿瘤用药、内分泌用药、消化系统用药、心血管用药。
发行价格：
5.76
{"stockData":{"symbol":"000963","market":"SZ","secType":"STK","nameCN":"华东医药","latestPrice":26,"timestamp":1792652583000,"preClose":26.59,"halted":0,"volume":11926969,"delay":0,"changeRate":-0.0222,"floatShares":1753000000,"shares":1754000000,"eps":1.9731,"marketStatus":"已收盘","change":-0.59,"latestTime":"10-22 15:00:00","open":26.46,"high":26.51,"low":26,"amount":312000000,"amplitude":0.0192,"askPrice":26.01,"askSize":512,"bidPrice":26,"bidSize":130,"shortable":0,"etf":0,"ttmEps":1.9731,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792719000000},"marketStatusCode":5,"adr":0,"adjPreClose":26.59,"symbolType":"stock","openAndCloseTimeList":[[1792632600000,1792639800000],[1792645200000,1792652400000]],"highLimit":29.25,"lowLimit":23.93,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1753736848,"isCdr":false,"pbRate":1.83,"roa":"--","peRate":13.177234,"roe":"7.31%","epsLYR":1.9484,"committee":-0.127804,"marketValue":45597000000,"turnoverRate":0.0068,"status":1,"floatMarketCap":45578000000},"requestUrl":"/m/hq/s/000963/","defaultTab":"news","newsList":[{"id":"2677195216","title":"瑞银将华东医药评级下调至中性，目标价28元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2677195216","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677195216?lang=zh_cn&edition=full","pubTime":"2026-10-22 19:06","pubTimestamp":1792667193,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1969619763.USD","BK0209","BK0175","000963","BK0132","BK0183","LU2328871848.SGD","BK0187","BK0188","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677995340","title":"佐力药业：公司及子公司与华东医药的购销属于商业化业务往来","url":"https://stock-news.laohu8.com/highlight/detail?id=2677995340","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677995340?lang=zh_cn&edition=full","pubTime":"2026-10-22 17:12","pubTimestamp":1792660329,"startTime":"0","endTime":"0","summary":"公司及子公司与华东医药的购销属于商业化业务往来，基于市场化条件协商定价，不存在利益交换或利益输送。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200029340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","BK0209","BK0187","BK0196","BK0132","BK0042","LU2328871848.SGD","000963","BK0239","BK0183","300181","BK0175","BK0077","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677953822","title":"瑞银：降联邦制药评级至“中性” 重申先声药业为首选","url":"https://stock-news.laohu8.com/highlight/detail?id=2677953822","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677953822?lang=zh_cn&edition=full","pubTime":"2026-10-22 16:47","pubTimestamp":1792658820,"startTime":"0","endTime":"0","summary":"瑞银发布研报称，重新审视中国制药覆盖范围的增长前景，评估现有重磅产品是否已见顶，以及下一批50亿元人民币级产品可能来自何处;该行重申先声药业(02096)为首选，同时将联邦制药(03933)及 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261022/c680982128.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261022/c680982128.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0175","000963","BK0183","BK0209","BK0188","BK0132","LU1969619763.USD","BK0187","BK0196","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676845504","title":"华东医药（000963）披露控股子公司获得药物临床试验批准通知书，10月19日股价上涨0.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2676845504","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676845504?lang=zh_cn&edition=full","pubTime":"2026-10-19 17:22","pubTimestamp":1792401776,"startTime":"0","endTime":"0","summary":"截至2026年10月19日收盘，华东医药报收于26.49元，较前一交易日上涨0.91%，最新总市值为464.56亿元。近日，华东医药披露关于控股子公司获得药物临床试验批准通知书的公告。目前已在中国获批多项临床试验，本次获批进一步推进其在肿瘤治疗领域的发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900022058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","LU1969619763.USD","BK0196","000963","BK0183","LU2328871848.SGD","BK0187","BK0175","BK0188","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676509376","title":"全球首创三靶点激动剂DR10624入选AASLD最新突破摘要 华东医药代谢领域布局再获国际认可","url":"https://stock-news.laohu8.com/highlight/detail?id=2676509376","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676509376?lang=zh_cn&edition=full","pubTime":"2026-10-19 16:25","pubTimestamp":1792398300,"startTime":"0","endTime":"0","summary":"2026年10月19日，华东医药股份有限公司(以下简称“华东医药”)对外宣布，其控股子公司浙江道尔生物科技有限公司(以下简称“道尔生物”)自主研发的同类首创(First-in-class)长效三特异性激动 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261019/c680836661.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261019/c680836661.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0196","BK0183","BK0209","LU1969619763.USD","BK0175","LU2328871848.SGD","BK0132","BK0188","BK0187","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675594345","title":"华东医药最新公告：控股子公司注射用DR30206获批开展Ⅲ期非小细胞肺癌临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2675594345","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675594345?lang=zh_cn&edition=full","pubTime":"2026-10-16 20:00","pubTimestamp":1792152001,"startTime":"0","endTime":"0","summary":"华东医药(000963.SZ)公告称，公司控股子公司道尔生物收到国家药监局核准签发的《药物临床试验批准通知书》，注射用DR30206作为巩固治疗，拟用于同步/序贯放化疗后未进展的、局部晚期/不可切除(Ⅲ期)的非小细胞肺癌患者的临床试验申请获得批准。截至目前，全球尚无同时靶向PD-L1、VEGF和TGF-β的抗体融合蛋白药物上市。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600036145.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0187","BK0175","BK0209","000963","BK0188","BK0132","BK0196","LU2328871848.SGD","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675551279","title":"华东医药（000963）10月15日主力资金净卖出3845.29万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675551279","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675551279?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:07","pubTimestamp":1792112868,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月15日收盘，华东医药报收于26.3元，下跌0.04%，换手率0.69%，成交量12.14万手，成交额3.19亿元。近5日资金流向一览见下表：华东医药融资融券信息显示，融资方面，当日融资买入3191.03万元，融资偿还3715.36万元，融资净偿还524.33万元。华东医药主营业务：业务覆盖医药全产业链,拥有医药工业、医药商业、医美、工业微生物四大业务板块,已发展成为集医药研发、生产、经销为一体的大型综合性医药上市公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600008748.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","LU1969619763.USD","BK0132","000963","BK0183","BK0187","BK0209","BK0188","LU2328871848.SGD","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673049708","title":"华东医药（000963）9月30日主力资金净买入8495.75万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2673049708","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673049708?lang=zh_cn&edition=full","pubTime":"2026-10-08 09:06","pubTimestamp":1791421604,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月30日收盘，华东医药报收于27.69元，上涨3.13%，换手率1.87%，成交量32.84万手，成交额9.03亿元。近5日资金流向一览见下表：华东医药融资融券信息显示，融资方面，当日融资买入7944.21万元，融资偿还1.05亿元，融资净偿还2550.59万元。华东医药主营业务：业务覆盖医药全产业链,拥有医药工业、医药商业、医美、工业微生物四大业务板块,已发展成为集医药研发、生产、经销为一体的大型综合性医药上市公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800002985.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0175","BK0132","BK0188","BK0209","BK0196","BK0187","000963","LU1969619763.USD","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671270386","title":"华东医药（000963）披露2026年半年度报告，9月30日股价上涨3.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671270386","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671270386?lang=zh_cn&edition=full","pubTime":"2026-09-30 17:27","pubTimestamp":1790760432,"startTime":"0","endTime":"0","summary":"截至2026年9月30日收盘，华东医药报收于27.69元，较前一交易日上涨3.13%，最新总市值为485.61亿元。该股当日开盘26.73元，最高27.72元，最低26.69元，成交额达9.03亿元，换手率为1.87%。华东医药于近日披露《2026年半年度报告（英文版）》。报告显示，报告期内公司实现营业总收入22,066,646,185.69元，同比增长1.81%；归属于上市公司股东的净利润为1,860,757,262.42元，同比增长2.53%；扣除非经常性损益后的净利润为1,857,546,440.75元，同比增长5.44%。经营活动产生的现金流量净额为2,499,419,530.63元，同比增长1.73%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000027365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0175","BK0209","BK0196","BK0132","BK0188","BK0183","LU1969619763.USD","LU2328871848.SGD","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671279903","title":"华东医药：创新药收入占医药工业营收比重达到50%为公司争取达成的阶段性努力方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2671279903","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671279903?lang=zh_cn&edition=full","pubTime":"2026-09-30 15:37","pubTimestamp":1790753859,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药09月30日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘好 陈老师好 咱们公司工业板块规划《十五五》时 其中创新药大概什么时间营销占比能达到50%呢？您所提及的创新药收入占医药工业营收比重达到50%，为公司争取达成的阶段性努力方向。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000019744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","000963","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671329784","title":"华东医药：HDM1002片是公司内分泌/代谢赛道重点自研创新品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2671329784","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671329784?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:48","pubTimestamp":1790671691,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药09月29日在投资者关系平台上答复投资者关心的问题。投资者提问：随着全球减重药市场从注射制剂逐步向口服制剂拓展，公司如何看待口服GLP-1未来在整个代谢药市场中的市场空间？HDM1002片是公司内分泌/代谢赛道重点自研创新品种，在整体创新药战略中占据重要地位。该产品减重适应症Ⅲ期已取得积极结果，降糖适应症正在同步推进Ⅲ期，是公司GLP-1差异化管线矩阵的重要一环。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900027429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","BK0188","LU2328871848.SGD","BK0175","LU1969619763.USD","BK0132","BK0196","BK0187","BK0183","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671297854","title":"华东医药：创新产品业务收入占比将稳步提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2671297854","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671297854?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:45","pubTimestamp":1790671516,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药09月29日在投资者关系平台上答复投资者关心的问题。随着公司创新业务持续快速发展，创新产品业务收入占比将稳步提升。成熟业务作为公司经营基本盘，持续贡献稳定营收与经营性现金流，为创新研发投入提供坚实保障。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900027348.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0188","BK0196","BK0209","LU1969619763.USD","BK0132","BK0183","LU2328871848.SGD","000963","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671292095","title":"华东医药：HDM1002、HDM1005、DR10624为该治疗领域的重点在研产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2671292095","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671292095?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:39","pubTimestamp":1790671148,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药09月29日在投资者关系平台上答复投资者关心的问题。投资者提问：目前公司围绕肥胖及代谢领域已经形成HDM1002、HDM1005、DR10624等多产品梯队，公司未来是否有意将代谢领域打造成为继消化、内分泌等优势领域之后新的核心增长平台？内分泌/代谢领域是公司医药工业的传统优势治疗领域，HDM1002、HDM1005、DR10624为该治疗领域的重点在研产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900027202.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2328871848.SGD","000963","BK0175","BK0196","BK0209","BK0187","BK0183","BK0132","BK0188","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671229217","title":"华东医药：HDM1002拥有亮眼的减重Ⅲ期临床结果与差异化优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2671229217","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671229217?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:36","pubTimestamp":1790670968,"startTime":"0","endTime":"0","summary":"投资者提问：随着HDM1002 III期临床取得积极结果并即将申报上市，未来HDM1002商业化后，公司对其销售放量有哪些核心优势？如后续HDM1002顺利获批上市，产品放量主要依托两大核心条件。二是HDM1002拥有亮眼的减重Ⅲ期临床结果与差异化优势，作为每日一次口服小分子GLP-1激动剂，52 周治疗周期减重效果持续，未观察到减重平台期；除减重作用外，还可改善肝脏脂肪、优化体成分，保护瘦体重，多项心血管代谢指标同步获益；整体安全性良好，给药不受进食饮水限制。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900027132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0187","BK0175","BK0209","000963","BK0188","BK0132","BK0196","LU2328871848.SGD","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671617312","title":"华东医药HDM1002片取得顶线结果 未来商业化价值几何？","url":"https://stock-news.laohu8.com/highlight/detail?id=2671617312","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671617312?lang=zh_cn&edition=full","pubTime":"2026-09-29 09:36","pubTimestamp":1790645760,"startTime":"0","endTime":"0","summary":"近日，华东医药发布公告称，其全资子公司中美华东自主研发的1类创新药、口服小分子GLP-1受体激动剂HDM1002片用于超重或肥胖人群体重管理的中国Ⅲ期临床研究取得积极顶线结果，已完成Pre-NDA沟通，即将正式递交上市申请。作为华东医药内分泌代谢赛道的核心创新品种，HDM1002的临床进展与商业化潜力一直是资本市场关注焦点。患者总人数方面，HDM1002核心覆盖具备药物减重治疗指征的超重与肥胖人群。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-09-29/doc-initmzhp3097769.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1969619763.USD","000963","BK0196","BK0209","LU2328871848.SGD","BK0132","BK0188","BK0175","BK0187","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670803842","title":"华东医药：HDM1005体重管理适应症中国III期临床研究已于近期顺利达成40周主要终点的期中分析","url":"https://stock-news.laohu8.com/highlight/detail?id=2670803842","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670803842?lang=zh_cn&edition=full","pubTime":"2026-09-28 16:33","pubTimestamp":1790584387,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药(000963)09月28日在投资者关系平台上答复投资者关心的问题。投资者提问：HDM1005 体重管理 III 期 40 周数据是否已读出？预计何时、以何种方式对外披露？华东医药回复：您好！HDM1005体重管理适应症中国III期临床研究已于近期顺利达成40周主要终点的期中分析。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。相关 ETF责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800021309.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2328871848.SGD","000963","BK0175","BK0196","BK0209","BK0187","BK0183","BK0132","BK0188","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670408002","title":"华东医药最新公告：全资子公司创新GLP-1靶点口服小分子激动剂HDM1002片减重Ⅲ期研究获得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2670408002","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670408002?lang=zh_cn&edition=full","pubTime":"2026-09-27 16:19","pubTimestamp":1790497177,"startTime":"0","endTime":"0","summary":"华东医药(000963.SZ)公告称，公司全资子公司中美华东自主研发的1类创新药HDM1002片用于超重或肥胖人群体重管理的中国Ⅲ期临床研究取得积极顶线结果。研究显示，各剂量组第44周达到全部主要终点与关键次要终点，第52周体重较基线平均下降10.7%与12.2%，未观察到减重平台期。同时观察到肝脏脂肪含量大幅降低、体成分优化及多项心血管代谢指标改善，安全性特征良好。公司已完成Pre-NDA沟通，即将正式递交上市申请。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092700001023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","LU2328871848.SGD","BK0183","BK0187","BK0196","BK0132","BK0209","BK0175","000963","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669845749","title":"华东医药：工业微生物板块持续夯实xRNA原料、特色原料药&中间体、大健康&生物材料、动物保健四大业务布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2669845749","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669845749?lang=zh_cn&edition=full","pubTime":"2026-09-24 15:21","pubTimestamp":1790234468,"startTime":"0","endTime":"0","summary":"公司工业微生物板块持续夯实xRNA原料、特色原料药&中间体、大健康&生物材料、动物保健四大业务布局，强化技术创新迭代与海内外市场拓展，将深度融入全球医药供应链作为现阶段核心工作目标，海内外重点客户开发取得阶段性成效。今年上半年，公司工业微生物海外业务销售增长33%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400021376.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","LU1969619763.USD","BK0188","BK0187","BK0209","BK0132","LU2328871848.SGD","000963","BK0175","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668495968","title":"华东医药加快再生医美布局，欣可丽美学独家合作引入ECM胶原蛋白MB007","url":"https://stock-news.laohu8.com/highlight/detail?id=2668495968","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668495968?lang=zh_cn&edition=full","pubTime":"2026-09-17 17:10","pubTimestamp":1789636203,"startTime":"0","endTime":"0","summary":"2026年9月17日，华东医药股份有限公司宣布，其全资子公司欣可丽美学(杭州)医疗科技有限公司与北京美柏医药生物技术发展有限公司及湖南美柏生物医药有限公司正式签署战略合作协议，就细胞外基质胶原蛋白MB007产品在中国市场达成独家战略合作。 此次合作是华东医药在再生医美材料领域从传统填充向新型生物材料源头延伸的关键一步，也标志着公司在ECM胶原蛋白这一前沿赛道完成战略卡位。目前，美柏生物正在全力推进MB007的III期临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260917/32373220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU1969619763.USD","BK0132","BK0175","BK0196","BK0187","BK0188","000963","BK0183","BK0209","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668950970","title":"华东医药：目前和解谈判仍在推进过程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2668950970","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668950970?lang=zh_cn&edition=full","pubTime":"2026-09-17 16:42","pubTimestamp":1789634531,"startTime":"0","endTime":"0","summary":"证券之星消息，华东医药09月17日在投资者关系平台上答复投资者关心的问题。你所说的“针对前期延迟供货对应的和解事，双方经协商已取得积极进展，并将积极推进中国市场商业化供货事宜。”请问，和解协议何时能签，炎朵何时能在国内上市？目前和解谈判仍在推进过程中，尚未正式完成协议签署。公司正全力推动各项工作，力争尽快落实和解相关安排，推进中国市场商业化供货事宜。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091700025833.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","LU2328871848.SGD","BK0196","BK0132","BK0175","BK0187","BK0209","000963","LU1969619763.USD","BK0183"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792686899849,"stockEarnings":[{"period":"1week","weight":-0.0114},{"period":"1month","weight":-0.0233},{"period":"3month","weight":-0.0779},{"period":"6month","weight":-0.235},{"period":"1year","weight":-0.3267},{"period":"ytd","weight":-0.3178}],"compareEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":-0.0744},{"period":"3month","weight":-0.0409},{"period":"6month","weight":-0.1034},{"period":"1year","weight":-0.0653},{"period":"ytd","weight":-0.0783}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华东医药股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"100196人(较上一季度增加18.85%)","perCapita":"17495股","listingDate":"2000-01-27","address":"浙江省杭州市拱墅区中山北路439号4、7楼","registeredCapital":"175373万元","survey":" 华东医药股份有限公司的主营业务是专科、慢病及特殊用药领域的研发、生产和销售。公司的主要产品是慢性肾病用药、免疫用药、肿瘤用药、内分泌用药、消化系统用药、心血管用药。","listedPrice":5.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华东医药(000963)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华东医药(000963)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华东医药,000963,华东医药股票,华东医药股票老虎,华东医药股票老虎国际,华东医药行情,华东医药股票行情,华东医药股价,华东医药股市,华东医药股票价格,华东医药股票交易,华东医药股票购买,华东医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华东医药(000963)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华东医药(000963)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}